Otherapy and mixture E/S+N had considerable reductions in LDL size, whereas compared with E/S, the mixture E/S+N created a considerable improve in LDL size.Journal from the American Heart AssociationCombination Therapy and Lipoprotein Particle NumberLe et alORIGINAL RESEARCHTable 2. % Alterations From Baseline in Lipids, LDL-P, HDL-P, and LDL and HDL SizeN Parameter (n=124) E/S (n=160) E/S+N (n=294) Treatment Distinction E/S+N vs N E/S+N vs E/S E/S vs NLDL-P Baseline imply (SD), nmol/L Study-end imply (SD), nmol/L Adjust from baseline LDL-S Baseline mean (SD), nm Study-end imply (SD), nm Alter from baseline HDL-P Baseline mean (SD), nmol/L Study end mean (SD), nmol/L Transform from baseline HDL-S Baseline mean (SD), nm Study-end imply (SD), nm Transform from baseline LDL-C Baseline imply (SD), mmol/L Study-end mean (SD), mmol/L Modify from baseline HDL-C Baseline imply (SD), mmol/L Study-end imply (SD), mmol/L Change from baseline ApoB Baseline mean (SD), g/L Study-end mean (SD), g/L Modify from baseline ApoA-I Baseline imply (SD), g/L Study-end mean (SD), g/L Transform from baseline Non-HDL-C Baseline imply (SD), mmol/L Study-end mean (SD), mmol/L Change from baseline TG Baseline imply (SD), mmol/L Study-end mean (SD), mmol/L Transform from baseline 1.9 (0.9) 1.3 (0.six) 6.42.0 (1.0) 1.6 (0.7) 5.71.9 (0.9) 1.two (0.6) six.6– — 0.two — — 0.9 — — ten.7*Continued1725.four (333.four) 1341.4 (346.four) 1.1758.2 (332.0) 1095.four (255.9) 6.1721.six (302.3) 890.two (355.3) 7.– — 6.1 — — .0 — — 6.3 — — 1.6 — — 8.6 — — 1.three — — eight.six — — .8 — — three. — — 0.9 — — 1.3 — — 3.three — — five.9– — .2* — — 21.six — — .4 — — 7.1 — — . — — five.2– — .3– — 3.0 — — .Theaflavin Purity 3– — 3.3– — 0.3– — 0.2– — .9– — 5.121.0 (0.7) 21.four (0.5) 2.20.9 (0.6) 20.6 (0.5) .20.9 (0.six) 20.9 (0.5) 0.32.0 (six.0) 34.7 (five.eight) 9.32.0 (six.0) 35.7 (six.0) 12.32.0 (six.0) 37.0 (six.3) 16.eight.6 (0.4) 9.two (0.six) five.98.six (0.4) eight.7 (0.four) 1.68.7 (0.four) 9.three (0.6) 7.54.1 (0.six) 3.two (0.7) 0.31.3 (0.four) 1.six (0.4) 28.4.0 (0.6) 1.9 (0.five) three.71.three (0.3) 1.three (0.3) 7.4.0 (0.six) 1.6 (0.7) eight.91.3 (0.three) 1.six (0.7) 29.1.five (0.two) 1.2 (0.2) 9.1.five (0.2) 0.9 (0.2) 0.1.five (0.two) 0.6 (0.two) eight.1.six (0.three) 1.eight (0.3) 11.1.6 (0.three) 1.7 (0.3) three.1.six (0.3) 1.eight (0.three) 10.five.0 (0.7) 3.eight (0.9) two.5.0 (0.7) 2.6 (0.6) 7.four.9 (0.7) 2.2 (0.9) 5.DOI: 10.1161/JAHA.113.Journal in the American Heart AssociationCombination Therapy and Lipoprotein Particle NumberLe et alORIGINAL RESEARCHTable 2. ContinuedN Parameter (n=124) E/S (n=160) E/S+N (n=294) Remedy Distinction E/S+N vs N E/S+N vs E/S E/S vs NTC Baseline imply (SD), mmol/L Study-end imply (SD), mmol/L Transform from baseline six.6-Benzylaminopurine web three (0.PMID:27108903 7) five.five (0.7) two.six.two (0.7) three.9 (0.7) six.6.two (0.7) three.eight (0.8) eight.– — 6.– — .– — 4.6To convert SI units to conventional units, multiply by 0.0259 for LDL-C, HDL-C, non-HDL-C, and TC; by 0.01 for apoB and apoAI, and by 0.0113 for TG. N indicates extended-release niacin (to two g/day); E/S, ezetimibe (ten mg/day)/simvastatin (20 mg/day); LDL-P, low-density lipoprotein particle quantity; HDL-P, high-density lipoprotein particle quantity; SD, standard deviation; LDL-S, low-density lipoprotein size; HDL-S, high-density lipoprotein size; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ApoB, apolipoprotein B; ApoA-I, apolipoprotein A-I; TG, triglycerides; TC, total cholesterol. *P0.05; P0.01; 0.001; �P0.001; P0.05.There were statistically substantial increases in HDL-P in all 3 therapy groups (Table 2). When E/S was coadministere.